

Learning Objectives

After completing this activity, the participant should be better able to:

- Select lung cancer patients for personalized chemotherapy based on new molecular profiling based guidelines
- Identify the role of emerging technology of liquid biopsy mutation testing in the management of non-small cell lung cancer (NSCLC)
- Outline the clinical data supporting the optimal use of EGFR inhibitors in the treatment of NSCLC
- Identify strategies in the treatment of NSCLC patients with ALK inhibitors
- Identifying optimal treatment options for NSCLC patients without actionable mutations
- Identify strategies to overcome secondary or acquired EGFR and ALK TKI resistance in patients with NSCLC
- Identify the role of personalized maintenance therapy in patients with the nonsquamous NSCLC
- Outline the clinical data supporting the optimal use of anti-PD-1 antibodies in the treatment of NSCLC
- Outline the clinical data supporting the optimal use of anti-PD-L1 antibodies in the treatment of NSCLC
- Discuss immunotherapy and targeted therapy options for small cell lung cancer
- Discuss the supportive care issues in the era of targeted therapy and immunotherapy options for NSCLC